Genome-wide genetic variation and molecular surveillance of drug resistance in Plasmodium falciparum isolates from asymptomatic individuals in Ouélessébougou, Mali

Autor: Leen N. Vanheer, Almahamoudou Mahamar, Emilia Manko, Sidi M. Niambele, Koualy Sanogo, Ahamadou Youssouf, Adama Dembele, Makonon Diallo, Seydina O. Maguiraga, Jody Phelan, Ashley Osborne, Anton Spadar, Merel J. Smit, Teun Bousema, Chris Drakeley, Taane G. Clark, William Stone, Alassane Dicko, Susana Campino

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)

Abstract Sequence analysis of Plasmodium falciparum parasites is informative in ensuring sustained success of malaria control programmes. Whole-genome sequencing technologies provide insights into the epidemiology and genome-wide variation of P. falc

Externí odkaz: https://doaj.org/article/1b0a0aff8b5f4741830b1dd2c4d9313e

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

Autor: Saskia C van der Boor, Merel J Smit, Stijn W van Beek, Jordache Ramjith, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Peter Pickkers, Yimin Wu, Emily Locke, Shwu-Maan Lee, John Aponte, C Richter King, Ashley J Birkett, Kazutoyo Miura, Morolayo A Ayorinde, Robert W Sauerwein, Rob ter Heine, Christian F Ockenhouse, Teun Bousema, Matthijs M Jore, Matthew B B McCall

Publikováno v: Lancet Infectious Diseases, 22, 1596-1605
Lancet Infectious Diseases, 22, 11, pp. 1596-1605

Contains fulltext : 287660.pdf (Publisher’s version ) (Open Access) BACKGROUND: Malaria elimination requires interruption of the highly efficient transmission of Plasmodium parasites by mosquitoes. TB31F is a humanised monoclonal antibody that bind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6447ac72a6a077d34ada58b429987eb
https://doi.org/10.1016/s1473-3099(22)00428-5

First-in-human use of a modular capsid virus-like vaccine platform:An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

Autor: Merel J Smit, Adam F Sander, Maud B P A Ariaans, Cyrielle Fougeroux, Constanze Heinzel, Rolf Fendel, Meral Esen, Peter G Kremsner, Rob ter Heine, Heiman F Wertheim, Manja Idorn, Søren Riis Paludan, Alexander P Underwood, Alekxander Binderup, Santseharay Ramirez, Jens Bukh, Max Soegaard, Sayit M Erdogan, Tobias Gustavsson, Stine Clemmensen, Thor G Theander, Ali Salanti, Mette Hamborg, Willem A de Jongh, Matthew B B McCall, Morten A Nielsen, Benjamin G Mordmüller, Robert Dagil, Louise Goksøyr, Thomas M Hulen, Christoph Janitzek, Daniel S Jensen, Sune Justesen, Paul K Khalifé, Andrea Kreidenweiss, Telma Lança, Olivia Lie-Andersen, Karina Teelen, Elena Vidal-Calvo

Publikováno v: Smit, M J & COUGH-1 trial study group 2023, ' First-in-human use of a modular capsid virus-like vaccine platform : An open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 ', The Lancet Microbe, vol. 4, no. 3, pp. e140-e148 . https://doi.org/10.1016/S2666-5247(22)00337-8
The Lancet Microbe, 4, 3, pp. e140-e148
The Lancet Microbe, 4, e140-e148

Contains fulltext : 291067.pdf (Publisher’s version ) (Open Access) BACKGROUND: Capsid virus-like particles (cVLP) have proven safe and immunogenic and can be a versatile platform to counter pandemics. We aimed to clinically test a modular cVLP COV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14ac00b940c34782ba1e1c8bde5833a
https://curis.ku.dk/ws/files/340399546/1_s2.0_S2666524722003378_main.pdf

Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial

Autor: Will Stone, Almahamoudou Mahamar, Merel J Smit, Koualy Sanogo, Youssouf Sinaba, Sidi M Niambele, Adama Sacko, Sekouba Keita, Oumar M Dicko, Makonon Diallo, Seydina O Maguiraga, Siaka Samake, Oumar Attaher, Kjerstin Lanke, Rob ter Heine, John Bradley, Matthew B B McCall, Djibrilla Issiaka, Sekou F Traore, Teun Bousema, Chris Drakeley, Alassane Dicko

Publikováno v: The Lancet Microbe, 3, 5, pp. e336-e347
The Lancet Microbe, 3, e336-e347
Lancet Microbe

Contains fulltext : 251206.pdf (Publisher’s version ) (Open Access) BACKGROUND: Tafenoquine was recently approved as a prophylaxis and radical cure for Plasmodium vivax infection, but its Plasmodium falciparum transmission-blocking efficacy is uncl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63e5fc39b06e4b81e3408a987411dab3